|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.140 USD | -5.91% |
|
-13.03% | -42.58% |
Company Valuation: Altimmune, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 417 | 363.1 | 808.4 | 604.4 | 512.8 | 335.8 | - | - |
| Change | - | -12.92% | 122.62% | -25.23% | -15.16% | -34.52% | - | - |
| Enterprise Value (EV) 1 | 417 | 363.1 | 697.3 | 469.3 | 380.9 | 187.7 | 144.1 | 9.624 |
| Change | - | -12.92% | 92.02% | -32.7% | -18.84% | -50.73% | -23.21% | -93.32% |
| P/E ratio | -5.91x | -3.9x | -9.09x | -6.78x | -5.38x | -3.23x | -2.7x | -3.06x |
| PBR | - | - | - | - | 4.22x | 4.15x | 2.21x | 1.79x |
| PEG | - | -0.2x | 0.4x | 0.82x | 0.3x | 0.72x | -0.1x | 0.3x |
| Capitalization / Revenue | 50.9x | 82.3x | -11,889x | 1,419x | 25,640x | 665x | 15.1x | 18.2x |
| EV / Revenue | 50.9x | 82.3x | -10,255x | 1,102x | 19,044x | 372x | 6.48x | 0.52x |
| EV / EBITDA | - | -3.77x | -7.93x | -4.92x | -3.7x | -1.73x | -0.99x | -0.06x |
| EV / EBIT | -7.61x | -4.25x | -7.95x | -5.62x | -3.69x | -1.69x | -1.18x | -0.06x |
| EV / FCF | -12x | -4.02x | -11.1x | -6.19x | -4.77x | -2.26x | -1.28x | -0.06x |
| FCF Yield | -8.31% | -24.9% | -8.99% | -16.2% | -21% | -44.3% | -78.3% | -1,659% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.91 | -2.35 | -1.81 | -1.66 | -1.34 | -1.28 | -1.533 | -1.351 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 8.185 | 4.41 | -0.068 | 0.426 | 0.02 | 0.5047 | 22.23 | 18.41 |
| EBITDA 1 | - | -96.36 | -87.94 | -95.45 | -102.9 | -108.2 | -145.3 | -174.3 |
| EBIT 1 | -54.8 | -85.54 | -87.74 | -83.51 | -103.2 | -111 | -121.8 | -161.1 |
| Net income 1 | -49.04 | -97.09 | -84.71 | -88.45 | -95.06 | -106.4 | -140.1 | -148.5 |
| Net Debt 1 | - | - | -111.1 | -135.2 | -131.9 | -148.1 | -191.7 | -326.2 |
| Reference price 2 | 11.280 | 9.160 | 16.450 | 11.250 | 7.210 | 4.140 | 4.140 | 4.140 |
| Nbr of stocks (in thousands) | 36,968 | 39,644 | 49,146 | 53,729 | 71,125 | 81,107 | - | - |
| Announcement Date | 2/25/21 | 3/15/22 | 2/28/23 | 3/27/24 | 2/27/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.23x | 371.84x | -1.73x | -.--% | 336M | ||
| 49.18x | 8.36x | 37.25x | -.--% | 34.39B | ||
| 18.86x | 4.69x | 12.92x | 1.56% | 30.84B | ||
| -23.93x | 5.95x | -9.71x | -.--% | 27.8B | ||
| -18.38x | 40.98x | -20.16x | -.--% | 18.65B | ||
| -58.52x | - | -58.82x | -.--% | 18.57B | ||
| 25.23x | 4.43x | 12.85x | -.--% | 13.81B | ||
| 13.35x | 2.62x | 7.41x | -.--% | 13.28B | ||
| 2226.46x | 26.4x | 299.15x | -.--% | 12.94B | ||
| 19.46x | 4.69x | 13.45x | -.--% | 12.23B | ||
| Average | 224.85x | 52.22x | 29.26x | 0.16% | 18.29B | |
| Weighted average by Cap. | 162.75x | 12.06x | 23.26x | 0.26% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ALT Stock
- Valuation Altimmune, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition